Clinical Evaluation of Human Papillomavirus DNA Genotyping Assay to Diagnose Women Cervical Cancer

´ëÇÑÀÇ»ý¸í°úÇÐȸÁö 2012³â 18±Ç 2È£ p.123 ~ p.130

±è¼ºÇö(Kim Sung-Hyun) - Yonsei University College of Health Science Department of Biomedical Laboratory Science
À̵¿¼·(Lee Dong-Sup) - Yonsei University Wonju College of Health Sciences Department of Biomedical Laboratory Science
±è¿¹Àº(Kim Ye-un) - Yonsei University Wonju College of Health Sciences Department of Biomedical Laboratory Science
±è±âÇõ(Kim Gee-Hyuk) - Yonsei University Wonju College of Health Sciences Department of Biomedical Laboratory Science
¹Ú»óÁ¤(Park Sang-Jung) - Yonsei University College of Health Science Department of Biomedical Laboratory Science
ÃÖ¿¬ÀÓ(Choi Yeon-Im) - Yonsei University College of Health Science Department of Biomedical Laboratory Science
±èÅ¿ì(Kim Tae-Ue) - Yonsei University College of Health Science Department of Biomedical Laboratory Science
¹Ú±¤ÇÏ(Park Kwang-Hwa) - Yonsei University Wonju College of Medicine Department of Pathology
ÀÌÇý¿µ(Lee Hye-Young) - Yonsei University College of Health Science Department of Biomedical Laboratory Science

Abstract

In this study, we evaluated the human papillomavirus (HPV) genotyping test called MolecuTech REBA HPV-ID¢ç (YD Diagnostics, Seoul, Korea) for 704 women who also had cervical cytological evaluations by Thin Prep. The infection rate of high-risk HPV genotypes was 56.6% in patients with normal cytology, 59.8% in those with benign, low-grade squamous intraepithelial lesions, 51.4% in those with atypical squamous cells of uncertain significance, 92.3% in those with high-grade squamous intraepithelial lesions, and 94.1% in those with squamous cell carcinoma or adenocarcinoma. HPV 16 was the most common genotype detected in any lesion, followed by HPV 53, 58, 33, 52, 45, 31, and 35, in order. The HPV DNA test with PCR-REBA is a very highly sensitive, but less specific, method. The infection rates and HPV genotype distribution of non-Korean people versus people from South Korea showed regional differences.

Å°¿öµå

Human papillomavirus (HPV), Women cervical cancer, Clinical evaluation, PCR-REBA
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸°á°ú ÀڱðæºÎÀÇ ¼¼Æ÷º´¸®ÇÐÀû À¸·Î SCC, HSIL¿¡¼­ÀÇ HPV °íÀ§Ç豺ÀÇ °¨¿°·üÀÌ ¾à 92% ÀÌ»óÀ¸·Î °ËÃâµÇ¾ú°í, HPV ÀúÀ§Ç豺ÀÇ °¨¿°·üÀº ¾à 3% ¹Ì¸¸À¸·Î ³ªÅ¸³µÀ¸¸ç, ¶ÇÇÑ Á¶Á÷º´¸®ÇÐÀû °íµî±Þ º´ º¯ÀÎ Invasive cancer, CIN-2, CIN-3, CIS¿¡¼­ÀÇ HPV °íÀ§ Ç豺ÀÇ °¨¿°·üÀÌ ¾à 85% ÀÌ»óÀ¸·Î °ËÃâµÇ¾ú°í, HPV Àú À§Ç豺ÀÇ °¨¿°·üÀº ¾à 4% ¹Ì¸¸À¸·Î ³ªÅ¸³µ±â ¶§¹®¿¡ °í µî±Þ º´º¯¿¡¼­ÀÇ HPV DNA À¯ÀüÀÚÇü °Ë»ç¹ýÀÇ ºÐ¼®Àû ¹Î°¨µµ³ª ÀÓ»óÀû ƯÀ̵µ°¡ ¸ðµÎ ¶Ù¾î³²À» ¾Ë ¼ö ÀÖ¾ú´Ù.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå